Monitoring Clinical Trials Of Drugs By Industry Sponsors Quiz

All unused investigational agents are expected to be returned to the sponsor at the:

Which of the following should take place during periodic site visits?

Which of the following best describes when the majority of case report form (CRF) data are verified against source record information?

When should the sponsor-monitor conduct the most detailed review of the study protocol with the site's study staff?

The FDA requires retention of investigational drug study records for:

Which monitoring visit would NOT include an inventory of investigational agents?